Thyroid-specific ablation of the Carney complex gene, PRKAR1A, results in hyperthyroidism and follicular thyroid cancer

Endocrine-Related Cancer

Volumn 19, Issue 3, 2012, Pages 435-446

  Pringle, Daphne R ^a   Yin, Zhirong ^a,c   Lee, Audrey A ^a   Manchanda, Parmeet K ^a   Yu, Lianbo ^a   Parlow, Alfred F ^b   Jarjoura, David ^a   La Perle, Krista M D ^a   Kirschner, Lawrence S ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN PRKAR1A; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARNEY COMPLEX; CONTROLLED STUDY; GENE MUTATION; HYPERTHYROIDISM; IN VITRO STUDY; KNOCKOUT GENE; LOSS OF FUNCTION MUTATION; MOUSE; NONHUMAN; PHENOTYPE; THYROID FOLLICULAR CARCINOMA; TISSUE SPECIFICITY; TUMOR CELL CULTURE;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CYCLIC AMP-DEPENDENT PROTEIN KINASE RIALPHA SUBUNIT; DISEASE MODELS, ANIMAL; HYPERTHYROIDISM; MICE; MICE, KNOCKOUT; STAT3 TRANSCRIPTION FACTOR; THYROID GLAND; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84862670880     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0306     Document Type: Article

References (49)

1. Ambesi-Impiombato FS, Parks LA & Coon HG 1980 Culture of hormone-dependent functional epithelial cells from rat thyroids. PNAS 77 3455-3459. (doi:10.1073/pnas.77.6.3455)
2. Aschebrook-Kilfoy B, Ward MH, Sabra MM & Devesa SS 2010 Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid 21 125-134. (doi:10.1089/thy.2010.0021)
3. Bertherat J, Horvath A, Groussin L, Grabar S, Boikos S, Cazabat L, Libe R, Rene-Corail F, Stergiopoulos S, Bourdeau I et al. 2009 Mutations in regulatory subunit type 1A of cyclic adenosine 50-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. Journal of Clinical Endocrinology and Metabolism 94 2085-2091. (doi:10.1210/jc.2008-2333)
4. Besic N, Auersperg M & Golouh R 1999 Prognostic factors in follicular carcinoma of the thyroid - a multivariate survival analysis. European Journal of Surgical Oncology 25 599-605. (doi:10.1053/ejso.1999.0714)
5. Brewer C, Yeager N & Di Cristofano A 2007 Thyroid-stimulating hormone initiated proliferative signals converge in vivo on the mTOR kinase without activating AKT. Cancer Research 67 8002-8006. (doi:10.1158/0008-5472.CAN-07- 2471)
6. Brzezianska E & Pastuszak-Lewandoska D 2011 A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm. Frontiers in Bioscience 16 422-439. (doi:10.2741/3696)
7. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK et al. 2005 A network-based analysis of systemic inflammation in humans. Nature 437 1032-1037. (doi:10.1038/nature03985)
8. Dauer DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R, Enkemann S, Jove R & Haura EB 2005 Stat3 regulates genes common to both wound healing and cancer. Oncogene 24 3397-3408. (doi:10.1038/sj.onc.1208469)
9. Diallo-Krou E, Yu J, Colby LA, Inoki K, Wilkinson JE, Thomas DG, Giordano TJ & Koenig RJ 2009 Paired box gene 8-peroxisome proliferator-activated receptor-γ fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice. Endocrinology 150 5181-5190. (doi:10.1210/en.2009-0701)
10. Dobson ME, Diallo-Krou E, Grachtchouk V, Yu J, Colby LA, Wilkinson JE, Giordano TJ & Koenig RJ 2011 Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARg fusion protein thyroid carcinoma. Endocrinology 152 4455-4465. (doi:10.1210/en.2011-1178)
11. Gordon A, Glazko G, Qiu X & Yakovlev A 2007 Control of the mean number of false discoveries, Bonferroni and stability of multiple testing. Annals of Applied Statistics 1 179-190. (doi:10.1214/07-AOAS102)
12. Hargadine HR, Lowenstein JM & Greenspan FS 1970 Elevated serum TSH in human thyroid cancer. Oncology 24 172-180. (doi:10.1159/000224517)
13. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC & Chen H 2008 Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. Journal of Clinical Endocrinology and Metabolism 93 809-814. (doi:10.1210/jc.2007-2215)
14. Hollander MC, Blumenthal GM & Dennis PA 2011 PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nature Reviews Cancer 11 289-301. (doi:10.1038/nrc3037)
15. Hwang JH, Kim DW, Suh JM, Kim H, Song JH, Hwang ES, Park KC, Chung HK, Kim JM, Lee TH et al. 2003 Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation. Molecular Endocrinology 17 1155-1166. (doi:10.1210/me.2002-0401)
16. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U & Speed TP 2003 Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4 249-264. (doi:10.1093/biostatistics/4.2.249)
17. Jeker LT, Hejazi M, Burek CL, Rose NR & Caturegli P 1999 Mouse thyroid primary culture. Biochemical and Biophysical Research Communications 257 511-515. (doi:10.1006/bbrc.1999.0468)
18. Jones GN, Tep C, Towns WH II, Mihai G, Tonks ID, Kay GF, Schmalbrock PM, Stemmer-Rachamimov AO, Yoon SO & Kirschner LS 2008 Tissue-specific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production. Neoplasia 10 1213-1221. (doi:10.1593/neo.08652)
19. Jones GN, Pringle DR, Yin Z, Carlton MM, Powell KA, Weinstein MB, Toribio RE, La Perle KM & Kirschner LS 2010 Neural crest-specific loss of Prkar1a causes perinatal lethality resulting from defects in intramembranous ossification. Molecular Endocrinology 24 1559-1568. (doi:10.1210/me.2009-0439)
20. Kato Y, Ying H, Willingham MC & Cheng SY 2004 A tumor suppressor role for thyroid hormone β receptor in a mouse model of thyroid carcinogenesis. Endocrinology 145 4430-4438. (doi:10.1210/en.2004-0612)
21. Kim TH, Lee SY, Rho JH, Jeong NY, Soung YH, Jo WS, Kang DY, Kim SH & Yoo YH 2009 Mutant p53 (G199V) gains antiapoptotic function through signal transducer and activator of transcription 3 in anaplastic thyroid cancer cells. Molecular Cancer Research 7 1645-1654. (doi:10.1158/1541-7786.MCR-09-0117)
22. Kinlaw WB, Ling NC & Oppenheimer JH 1989 Identification of rat S14 protein and comparison of its regulation with that of mRNA S14 employing synthetic peptide antisera. Journal of Biological Chemistry 264 19779-19783. (Pubitemid 20008088)
23. Kirschner LS, Sandrini F, Monbo J, Lin JP, Carney JA &Stratakis CA 2000 Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex. Human Molecular Genetics 9 3037-3046. (doi:10.1093/hmg/9.20.3037)
24. Kirschner LS, Kusewitt DF, Matyakhina L, Towns WH II, Carney JA, Westphal H & Stratakis CA 2005 A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Research 65 4506-4514. (doi:10.1158/0008-5472.CAN-05-0580)
25. Kusakabe T, Kawaguchi A, Kawaguchi R, Feigenbaum L &Kimura S 2004 Thyrocyte-specific expression of Cre recombinase in transgenic mice. Genesis 39 212-216. (doi:10.1002/gene.20043)
26. Lacroix L, Lazar V, Michiels S, Ripoche H, Dessen P, Talbot M, Caillou B, Levillain JP, Schlumberger M & Bidart JM 2005 Follicular thyroid tumors with the PAX8-PPARγ1 rearrangement display characteristic genetic alterations. American Journal of Pathology 167 223-231. (doi:10.1016/S0002- 9440(10)62967-7)
27. Lee E, Ahn MY, Kim HJ, Kim IY, Han SY, Kang TS, Hong JH, Park KL, Lee BM & Kim HS 2007 Effect of di(n-butyl) phthalate on testicular oxidative damage and antioxidant enzymes in hyperthyroid rats. Environmental Toxicology 22 245-255. (doi:10.1002/tox.20259)
28. Lefrancois-Martinez AM, Blondet-Trichard A, Binart N, Val P, Chambon C, Sahut-Barnola I, Pointud JC & Martinez A 2011 Transcriptional control of adrenal steroidogenesis: novel connection between JAK2 and PKA through stabilization of transcription factor CREB. Journal of Biological Chemistry 286 32976-32985. (doi:10.1074/jbc.M111.218016)
29. Lu C, Zhu X, Willingham MC & Cheng SY 2011 Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma. Oncogene 31 2007-2016. (doi:10.1038/onc.2011.390)
30. Martinez de Mena R, Scanlan TS & Obregon MJ 2010 The T3 receptor β1 isoform regulates UCP1 and D2 deiodinase in rat brown adipocytes. Endocrinology 151 5074-5083. (doi:10.1210/en.2010-0533)
31. Miller KA, Yeager N, Baker K, Liao XH, Refetoff S &Di Cristofano A 2009 Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Research 69 3689-3694. (doi:10.1158/0008-5472.CAN-09-0024)
32. Nadella KS & Kirschner LS 2005 Disruption of protein kinase A regulation causes immortalization and dysregulation of D-type cyclins. Cancer Research 65 10307-10315. (doi:10.1158/0008-5472.CAN-05-3183)
33. Nadella KS, Jones GN, Trimboli A, Stratakis CA, Leone G &Kirschner LS 2008 Targeted deletion of Prkar1a reveals a role for protein kinase A in mesenchymal-to-epithelial transition. Cancer Research 68 2671-2677. (doi:10.1158/0008-5472.CAN-07-6002)
34. Nagy R, Ganapathi S, Comeras I, Peterson C, Orloff M, Porter K, Eng C, Ringel MD & Kloos RT 2011 Frequency of germline PTEN mutations in differentiated thyroid cancer. Thyroid 21 505-510. (doi:10.1089/thy.2010.0365)
35. Narayan P & Towle HC 1985 Stabilization of a specific nuclear mRNA precursor by thyroid hormone. Molecular and Cellular Biology 5 2642-2646. (doi:10.1128/MCB.5.10.2642)
36. Niepomniszcze H, Suarez H, Pitoia F, Pignatta A, Danilowicz K, Manavela M, Elsner B & Bruno OD 2006 Follicular carcinoma presenting as autonomous functioning thyroid nodule and containing an activating mutation of the TSH receptor (T620I) and a mutation of the Ki-RAS (G12C) genes. Thyroid 16 497-503. (doi:10.1089/thy.2006.16.497)
37. Nikiforov YE 2011 Molecular diagnostics of thyroid tumors. Archives of Pathology & Laboratory Medicine 135 569-577.
38. Plaza-Menacho I, van der Sluis T, Hollema H, Gimm O, Buys CH, Magee AI, Isacke CM, Hofstra RM & Eggen BJ 2007 Ras/ERK1/2-mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation. Journal of Biological Chemistry 282 6415-6424. (doi:10.1074/jbc.M608952200)
39. Rocha AS, Marques R, Bento I, Soares R, Magalhaes J, de Castro IV & Soares P 2007 Thyroid hormone receptor β mutations in the 'hot-spot region' are rare events in thyroid carcinomas. Journal of Endocrinology 192 83-86. (doi:10.1677/JOE-06-0009)
40. Sandrini F, Matyakhina L, Sarlis NJ, Kirschner LS, Farmakidis C, Gimm O & Stratakis CA 2002 Regulatory subunit type I-α of protein kinase A (PRKAR1A): a tumor-suppressor gene for sporadic thyroid cancer. Genes, Chromosomes &Cancer 35 182-192. (doi:10.1002/gcc.10112)
41. Sartor MA, Tomlinson CR, Wesselkamper SC, Sivaganesan S, Leikauf GD & Medvedovic M 2006 Intensity-based hierarchical Bayes method improves testing for differentially expressed genes in microarray experiments. BMC Bioinformatics 7 538. (doi:10.1186/1471-2105-7-538)
42. Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Tazi M, Bratasz A, Tong L, Rivera BK, Kalai T, Hideg K et al. 2010 Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: differential cytotoxicity in healthy and cancer cells. Free Radical Biology & Medicine 48 1228-1235. (doi:10.1016/j.freeradbiomed.2010.02.009)
43. Stratakis CA, Kirschner LS & Carney JA 2001 Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. Journal of Clinical Endocrinology and Metabolism 86 4041-4046. (doi:10.1210/jc.86.9.4041)
44. Tong X, Muchnik M, Chen Z, Patel M, Wu N, Joshi S, Rui L, Lazar MA & Yin L 2010 Transcriptional repressor E4-binding protein 4 (E4BP4) regulates metabolic hormone fibroblast growth factor 21 (FGF21) during circadian cycles and feeding. Journal of Biological Chemistry 285 36401-36409. (doi:10.1074/jbc.M110.172866)
45. Trovato M, Grosso M, Vitarelli E, Ruggeri RM, Alesci S, Trimarchi F, Barresi G & Benvenga S 2003 Distinctive expression of STAT3 in papillary thyroid carcinomas and a subset of follicular adenomas. Histology and Histopathology 18 393-399. (Pubitemid 36362056)
46. Yeager N, Klein-Szanto A, Kimura S & Di Cristofano A 2007 Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. Cancer Research 67 959-966. (doi:10.1158/0008-5472.CAN-06-3524)
47. Yin Z, Jones GN, Towns WH II, Zhang X, Abel ED, Binkley PF, Jarjoura D & Kirschner LS 2008a Heart-specific ablation of Prkar1a causes failure of heart development and myxomagenesis. Circulation 117 1414-1422. (doi:10.1161/CIRCULATIONAHA.107.759233)
48. Yin Z, Williams-Simons L, Parlow AF, Asa S & Kirschner LS 2008b Pituitary-specific knockout of the Carney complex gene Prkar1a leads to pituitary tumorigenesis. Molecular Endocrinology 22 380-387. (doi:10.1210/me.2006-0428)
49. Yu LB, Gulati P, Fernandez S, Pennell M, Kirschner L &Jarjoura D 2011 Fully moderated T-statistic for small sample size gene expression arrays. Statistical Applications in Genetics and Molecular Biology 10 42. (doi:10.2202/1544-6115.1701)